Connect with us

Hi, what are you looking for?

Monday, Apr 15, 2024
Mugglehead Magazine
Alternative investment news based in Vancouver, B.C.


Khiron launches new pot products in Europe

The products will be distributed via the company’s subsidiary Pharmadrug Production GmbH

Khiron launches new pot products in Europe
Photo via Khiron

Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) (Frankfurt: A2JMZC) continues to expand its presence and portfolio in Europe, with its latest new products being released in the next weeks.

On Thursday, the multinational operator headquartered in Toronto but with primary operations in Colombia announced it is adding products to its portfolio in the European market.

The products will be promoted to prescribers, pharmacies and patients and distributed through the company’s wholly-owned subsidiary Pharmadrug Production GmbH and will be available to pharmacies and patients in Germany and the United Kingdom in the next few weeks.

Khiron also will introduce “non-irradiated” flower varieties Khiron Gelato 19/1 and Khiron Caramel 5/7 which are popular in California and have a high demand in Europe.

The company will also bring a new THC-dominant full-spectrum extract Khiriox 25/1.

Pharmadrug GmbH is a EU-GMP and EU-GDP certified manufacturer and wholesaler of medicinal products for more than 30 years.

Read more: Khiron drops revenue by 4% to $4.5M in Q2

Read more: Khiron opens its first Zerenia Clinic in Brazil

“With the acquisition of Pharmadrug, Khiron is now able to completely control the value chain in Europe, and we can introduce new products that are in high demand in the European market with potential higher margins,” Khiron Europe president Franziska Katterbach.

“With these new additions to our medical portfolio, Khiron Europe now covers the entire spectrum of chemotypes, therapies and routes of administration in the interest of all our European prescribers and patients,” Katterbach said.

“With our new medical products, we offer patients what they want and need. Especially our new flower varieties Gelato and Caramel illustrate that medicine does not have to be bitter.”


Follow Mugglehead on Twitter

Like Mugglehead on Facebook

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like


Only patients diagnosed with chronic pain, mental health, neurological conditions and epilepsy will be able to get coverage


The government also revalidated medical conditions where medical practitioners have found cannabis to be effective


Khiron says it has developed a proven clinic business model with highly profitable medical cannabis sales in Colombia, the United Kingdom, Peru, Brazil and...


The Rio de Janeiro clinic has a capacity of 23,000 patient consultations per year